Says gaining market share in many geographies. Says strong biosimilar pipeline expected to deliver revenue in short term. Says planned generic launches in ’24-’25 with combined brand value of about $10B. Comments taken from Q4 earnings conference call.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TEVA:
